Cencora (COR) stock has drawn investor attention after recent trading performance, with the share price closing at $281.43. The move comes alongside mixed short term returns and a longer multi year track record.

Recent trading puts Cencora’s 30 day share price return at 9.20%, yet the stock is still down 16.95% year to date. Longer term total shareholder returns over three and five years remain positive, suggesting recent momentum is rebuilding after a weaker spell.

If you are weighing Cencora against other healthcare opportunities, this is a good moment to scan for peers using a dedicated screener for 39 healthcare AI stocks

So with Cencora stock rebounding over the past month but still weaker over the year and trading below some valuation estimates, is this an overlooked entry point, or is the market already pricing in the company’s future growth?

Most Popular Narrative: 20% Undervalued

Against Cencora’s last close at $281.43, the most followed narrative points to a fair value around $350.58. This frames the recent pullback as a discount to its modeled future cash generation and earnings power.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act. This improves supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Want to see what sits behind that margin story for Cencora? The narrative leans on measured revenue expansion, a steady lift in profitability, and a richer earnings multiple. The interesting part is how those ingredients combine over time to support that higher fair value, especially once capital allocation and buybacks are layered in.

Result: Fair Value of $350.58 (UNDERVALUED)

However, Cencora’s story still carries meaningful risks, including pressure on margins from lower fee biosimilars and generics, as well as regulatory or pricing changes that could compress profitability.

Next Steps

With Cencora carrying both clear risks and meaningful potential rewards, this is a moment to review the data yourself and decide promptly where you stand. To see that balance in one place, review the 5 key rewards and 1 important warning sign

Looking for more investment ideas beyond Cencora?

If you are serious about building a stronger portfolio, do not stop at Cencora. Use the Simply Wall Street Screener to compare fresh ideas side by side.

• Scan for potential value opportunities by reviewing companies featured in the 47 high quality undervalued stocks.
• Prioritize resilience and capital protection by focusing on candidates highlighted in the 68 resilient stocks with low risk scores.
• Hunt for underfollowed potential by checking the screener containing 20 high quality undiscovered gems before the crowd pays attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.